Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study

被引：3

作者：

Andre, T. ^{[1
,2
]}

Berton, D. ^{[3
,4
]}

Oaknin, A. ^{[5
]}

Moreno Garcia, V. ^{[6
]}

Curigliano, G. ^{[7
,8
]}

Trigo, J. ^{[9
]}

Barretina-Ginesta, M-P. ^{[10
]}

Ellard, S. ^{[11
]}

Tinker, A. V. ^{[12
]}

Miller, R. ^{[13
]}

Pikiel, J. ^{[14
]}

Boni, V. ^{[15
]}

Cresta, S. ^{[16
]}

Pothuri, B. ^{[17
]}

Perez, D. Roda ^{[18
]}

Drew, Y. ^{[19
]}

Veneris, J. ^{[20
]}

Im, E. ^{[21
]}

Banerjee, S. ^{[22
]}

机构：

[1] Sorbonne Univ, Med Oncol, Paris, France

[2] St Antoine Hosp, Paris, France

[3] GINECO, Med Oncol Dept, St Herblain, France

[4] Ctr Rene Gauducheau, Inst Cancerol lOuest, St Herblain, France

[5] Vall Hebron Inst Oncol VHIO, Vall DHebron Univ Hosp, Med Oncol, Barcelona, Spain

[6] Fdn Jimenez Diaz Hosp, START Madrid FJD, Clin Res, Madrid, Spain

[7] European Inst Oncol IRCCS, Div Early Drug Dev, IEO, Milan, Italy

[8] Univ Milan, Milan, Italy

[9] Hosp Ramon & Cajal, Med Oncol Dept, Madrid, Spain

[10] Inst Catala Oncol, Med Oncol Serv, Girona, Spain

[11] BC Canc Kelowna, Med Oncol, Vancouver, BC, Canada

[12] BC Canc, Med Oncol, Vancouver, BC, Canada

[13] UCL, St Bartholomews Hosp London, Med Oncol, London, England

[14] Reg Ctr Oncol, Med Oncol, Gdansk, Poland

[15] Hosp Univ HM Sanchinarro, START Madrid CIOCC, Ctr Integral Oncol Clara Campal, Early Drug Dev Unit, Madrid, Spain

[16] IRCCS Ist Nazl Tumori Fdn, Med Oncol, Milan, Italy

[17] NYU Langone Hlth, Laura & Isaac Perlmutter Canc Ctr, Gynecol Oncol Grp GOG, Obstet & Gynecol, New York, NY USA

[18] Univ Hosp, Dept Med Oncol, Valencia, Spain

[19] Newcastle Hosp NHS Fdn Trust, Northern Ctr Canc Care, Med Oncol, Newcastle Upon Tyne, Tyne & Wear, England

[20] GlaxoSmithKline, Oncol Clin Dept, Waltham, MA USA

[21] GlaxoSmithKline, Clin Dev, Waltham, MA USA

[22] Royal Marsden Hosp NHS Fdn Trust, Gynaecol Dept, London, England

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1375

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

991P

引用

页码：S845 / S846

页数：2

共 50 条

[31] A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor
Sawada, Takashi
Narukawa, Mamoru
CANCER CONTROL, 2024, 31
[32] Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder
Papakostas, GI
Petersen, T
Hughes, ME
Nierenberg, AA
Alpert, JE
Fava, M
PSYCHIATRY RESEARCH, 2004, 126 (03) : 287 - 290
[33] Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer
Meng, Lingbin
Thapa, Ram
Delgado, Maria G.
Gomez, Maria F.
Ji, Rui
Knepper, Todd C.
Hubbard, Joleen M.
Wang, Xuefeng
Permuth, Jennifer B.
Kim, Richard D.
Laber, Damian A.
Xie, Hao
JAMA NETWORK OPEN, 2023, 6 (06) : E2320035
[34] Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events
Pinter, Matthias
Kwanten, Wilhelmus J.
Jain, Rakesh K.
CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3803 - 3812
[35] Treatment-related adverse events of antibody-drug conjugates: review of clinical toxicity
Reactions Weekly, 2022, 1935 (1) : 12 - 12
[36] COST OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) IN SECOND-LINE (2L) ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): MATCH ADJUSTED INDIRECT COMPARISON (MAIC) OF NIVOLUMAB AND REGORAFENIB
Venkatachalam, M.
Stenehjem, D.
Parikh, N. D.
Singh, P.
Marett, B.
Sill, B.
Wisniewski, T.
Prakash, V
Shukla, P.
Korytowsky, B.
Siddiqui, M. K.
VALUE IN HEALTH, 2017, 20 (09) : A502 - A503
[37] The time course of adverse events (AEs) during dostarlimab treatment in mismatch mutation repair deficient (dMMR) and proficient (MMRp) endometrial cancer (EC) patients in the GARNET trial
Banerjee, Ashish
Oaknin, Ana
Gilbert, Lucy
Guo, Wei
Im, Ellie
Pothuri, Bhavana
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 162 - 162
[38] MANAGEMENT OF TREATMENT-RELATED ADVERSE EVENTS ASSOCIATED WITH NIVOLUMAB AND IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH METASTATIC MELANOMA, NSCLC, OR RCC.
Kannan, Rajni
Mitchell, Teresa
Sherry, Victoria
Pons, Alice
Kreamer, Kristen
Shames, Yelena
ONCOLOGY NURSING FORUM, 2017, 44 (02)
[39] Risk factors for treatment-related adverse events in cancer-bearing dogs receiving piroxicam
Eichstadt, L. R.
Moore, G. E.
Childress, M. O.
VETERINARY AND COMPARATIVE ONCOLOGY, 2017, 15 (04) : 1346 - 1353
[40] Tolerability and Treatment-Related Adverse Events of Upfront Pembrolizumab Combination Regimens in Advanced NSCLC Patients
Jahan, N.
Thein, K.
Sultan, A.
Swarup, S.
Mogollon-Duffo, F.
Adhikari, N.
Arevalo, M.
Htut, T.
Naing, T.
D'Cunha, N.
Rehman, S.
Hardwicke, F.
Tijani, L.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S726 - S726

← 1 2 3 4 5 →